aspergillosis

Aspergillus

  • most common species: A. fumigatus, A. flavus, A. niger, and the amphotericin-resistant A. terreus.
  • Aspergillus produces disease after inhalation of airborne spores (90%) and only occasionally by traumatic skin inoculation. Of all the fungi, Aspergillus is notable for the diverse settings in which it can occur and the various clinical manifestations it can produce.

Types

This patient most likely has invasive pulmonary aspergillosis (IPA).  Aspergillus has diverse presentations, including asymptomatic infection in immunocompetent hosts, allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma or cystic fibrosis, and various patterns of chronic PA.  Risk factors for chronic PA include prior lung disease such as pulmonary tuberculosis, ABPA, lung cancer, chronic obstructive pulmonary disease, and sarcoidosis.

Symptoms of IPA are nonspecific and usually mimic bronchopneumonia: fever unresponsive to antibiotics, cough, sputum production, and dyspnea.  Patients may also present with pleuritic chest pain (due to vascular invasion leading to thromboses that cause small pulmonary infarcts) and hemoptysis, which is usually mild.  IPA is one of the most common causes of hemoptysis in neutropenic patients.  Chest x-ray may not detect early-stage disease (ie, small nodules).  Chest computed tomography (CT) scan shows single or multiple nodules with or without cavitations and "halo sign" (nodules surrounded by ground-glass infiltrates).  Diagnosis is suggested by culture and histology.

Enzyme-linked immunosorbent assay on serum or bronchoalveolar lavage fluid can be used to detect galactomannan antigen (present in Aspergillus cell walls), especially in patients with hematologic malignancies.  Voriconazole has become the gold standard as primary therapy for invasive aspergillosis.  Voriconazole was more effective than amphotericin B as initial therapy for IPA and was associated with significantly improved survival (71% vs 58%, respectively) in a randomized trial (Choice A).

Invasive pulmonary aspergillosis

Invasive pulmonary aspergillosis:

  • most often occurs in immunosuppressed patients who are neutropenic or are HSC transplant recipients
  • starts in respiratory tract and then enters the circulatory system (angioinvasion). This is followed by the formation of a fungus-septic emboli complex with subsequent hematogenous dissemination.
  • Sx: most commonly pulmonary aspergillosis (60%), but sinusitis, brain abscess, endocarditis, disseminated infection, and osteomyelitis also may occur.
  • fever unresponsive to antibiotics
  • angioinvasive: hemoptysis
  • Dx:
    • blood cultures generally negative
    • serum galactomannan test testing is recommended
    • If the serum galactomannan result is negative, but the patient has strong risk factors, bronchoalveolar lavage with galactomannan and Aspergillus polymerase chain reaction (PCR) are recommended, followed by tissue biopsy, if necessary, to establish a definitive diagnosis.
    • Early CT of the chest in patients with suspected invasive pulmonary aspergillosis—with typical findings suggestive of septic emboli (nodules, often with a “halo sign”), thromboembolic pulmonary infarction (wedge-shaped peripheral densities), or necrosis with cavitation and a crescent sign—and the serum galactomannan assay can be useful in establishing a presumptive diagnosis of invasive infection, especially in neutropenic patients and hematopoietic stem cell transplant recipients, in whom the assay has a sensitivity of approximately 80%.
    • First-line treatment of invasive aspergillosis is with a triazole (voriconazole, posaconazole, or isavuconazole); amphotericin B deoxycholate or liposomal amphotericin B can be used for amphotericin-sensitive Aspergillus species if triazoles a re not available. When possible, reversal of immunosuppression improves treatment response.
    • Several antifungals have shown effectiveness in treating IPA. Early on, voriconazole demonstrated superiority to amphotericin, and isavuconazole has subsequently demonstrated equivalence to voriconazole. Amphotericin is often an effective drug for other fungal infections that are either very serious or may involve the CNS, but voriconazole and isavuconazole both cross the blood-brain barrier

  • septated hyphae differentiates from mucormycosis

  • voriconazole fist line treatment

  • if resistant use echinocandin and amphotericin B

chronic cavitary pulmonary aspergillosis

  • aspergillosis invades space damaged by something else
  • IgG, not IgE must be used for diagnosis
  • previous space with now with pleural thickening
  • must be there for more than 3 months
  • itraconazole and reduce immunosuppression
  • monitor treatment for 6 months Other forms of Aspergillus infection occur in different clinical settings. Chronic necrotizing aspergillosis is a semi-invasive indolent form of infection that does not disseminate and occurs in patients who have lesser degrees of immunosuppression (such as those who take chronic glucocorticoids or those who have intrinsic immune defects) or chronic pulmonary disease. Treatment is similar to that for invasive pulmonary aspergillosis.

Aspergilloma

  • usually not causing problem unless there's hemoptysis with sputum showing hyphal.
  • Serum IgG positive against aspergillus
  • if asymptomatic do not treat
  • azoles + surgery if hemoptysis Pulmonary aspergillomas (fungus balls consisting of hyphae, mucus, and cellular debris) may form in patients with pre-existing cavities, such as old tuberculosis cavities and in bullae of patients with COPD; the presence of significant hemoptysis is a potential complication. In the absence of associated symptoms or hemoptysis, pulmonary aspergillomas may not require therapy; however, in the setting of significant bleeding, surgical resection or embolization may be necessary. Antifungal therapy is typically not effective against pulmonary aspergillomas, and its role in aspergilloma treatment is unclear.

ABPA